Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors
Primary Purpose
Bladder Cancer
Status
Not yet recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Endoscopic fulguration
Sponsored by
About this trial
This is an interventional treatment trial for Bladder Cancer focused on measuring active surveillance, fulguration, bladder cancer
Eligibility Criteria
Inclusion Criteria:
- Recurrent Ta-T1a (above muscularis mucosa) LOW GRADE bladder tumor
- Accept cystoscopy surveillance
- Main lession less than 10mm
- Less than 7 lesions
- Negative or low grade cytology
- No solid aspect
Exclusion Criteria:
- previous High grade bladder cancer tumors
- previous Cis
- previous Upper Urinary Tract tumor
- previous pelvic radiotherapy
- hematuria
- meatal localisation
Sites / Locations
- Fernando Lozano Palacio
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
Active surveillance
endoscopic fulguration
Arm Description
After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery
After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode
Outcomes
Primary Outcome Measures
Progression rate
Number of patients that progress during the follow up
Complications rate
Number and grade of complications in both arms. Clavien Dindo Scale will be used
Secondary Outcome Measures
recurrence rate
number of recurrences
quality of life measured with CAVICAVENMI questionnaire
quality of life of the patients in both subgroups. CAVICAVENMI questionnaire will be used
Full Information
NCT ID
NCT05148728
First Posted
November 26, 2021
Last Updated
December 7, 2021
Sponsor
Vall Hebron Insitut Recerca
1. Study Identification
Unique Protocol Identification Number
NCT05148728
Brief Title
Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors
Official Title
Prospective Randomized Trial in Low Grade Bladder Tumors: Active Surveillance vs Endoscopic Fulguration.
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 15, 2021 (Anticipated)
Primary Completion Date
December 15, 2023 (Anticipated)
Study Completion Date
March 15, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vall Hebron Insitut Recerca
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Biological behabiour of low grade bladder cancer tumors is well known. They have a very high rate of recurrences during their follow up but very low (less than 1%) risk of progression.
Until now, the gold standard of any bladder recurrence for this patients is performing an immediate transurethral ressection of the tumor.
This surgery has risk of complications and, due to the low risk of these subgroup of tumors, sometimes it becomes an overtreatment for the patients.
This is the reason why new conservative or less invasive surgeries are proposed to follow up and treat these patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer
Keywords
active surveillance, fulguration, bladder cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Active surveillance
Arm Type
No Intervention
Arm Description
After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery
Arm Title
endoscopic fulguration
Arm Type
Active Comparator
Arm Description
After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode
Intervention Type
Procedure
Intervention Name(s)
Endoscopic fulguration
Other Intervention Name(s)
Active surveillance
Intervention Description
already included. WE will use Storz monopolar device for fulguration
Primary Outcome Measure Information:
Title
Progression rate
Description
Number of patients that progress during the follow up
Time Frame
two years
Title
Complications rate
Description
Number and grade of complications in both arms. Clavien Dindo Scale will be used
Time Frame
two years
Secondary Outcome Measure Information:
Title
recurrence rate
Description
number of recurrences
Time Frame
two years
Title
quality of life measured with CAVICAVENMI questionnaire
Description
quality of life of the patients in both subgroups. CAVICAVENMI questionnaire will be used
Time Frame
two years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Recurrent Ta-T1a (above muscularis mucosa) LOW GRADE bladder tumor
Accept cystoscopy surveillance
Main lession less than 10mm
Less than 7 lesions
Negative or low grade cytology
No solid aspect
Exclusion Criteria:
previous High grade bladder cancer tumors
previous Cis
previous Upper Urinary Tract tumor
previous pelvic radiotherapy
hematuria
meatal localisation
Facility Information:
Facility Name
Fernando Lozano Palacio
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fernando FL Lozano, MD
Phone
+34636244960
Email
flozano@vhebron.net
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
codified information (anonymous information)
IPD Sharing Time Frame
after completing the recruitment (two years), data will be available, for 5 years
Learn more about this trial
Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors
We'll reach out to this number within 24 hrs